Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Legal Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,003 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 17,557 · Balance 61,003 F1: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 17,557 | $66.28 | $1,163,748.19 |
DisclosureSEC source: 0001628280-26-060572 · wk-form4_1788475269.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,003 F1 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 20:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,273 | $56.05 | $71,351.65 |
DisclosureSEC source: 0001628280-26-019862 · wk-form4_1773953589.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,560 Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 34,690 | $0.00 Strike: $57.43 | $0.00 |
DisclosureSEC source: 0001628280-26-019010 · wk-form4_1773794885.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,690 Underlying: Common Stock · 34,690 shares Expires 2036-03-15 F3 · derivative.exercise_date: Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 14,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019010 · wk-form4_1773794885.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,833 F1 · price: Restricted stock units granted March 16, 2026. Price not applicable. F2 · balance_after: The Reporting Person's direct holdings have been adjusted by thirteen shares to correct a previous clerical error. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,177 | $58.51 | $419,926.27 |
DisclosureSEC source: 0001628280-26-019010 · wk-form4_1773794885.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,263 Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 26,061 | $61.36 | $1,599,102.96 |
DisclosureSEC source: 0001628280-26-012533 · wk-form4_1772155864.xml · nonDerivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,453 Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012533 · wk-form4_1772155864.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,514 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012533 · wk-form4_1772155864.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,142 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-012533 · wk-form4_1772155864.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,467 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| April 30, 2025 Filed Feb 13, 2026 23:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 375 | $54.14 | $20,301.38 |
DisclosureSEC source: 0001628280-26-008216 · wk-form5_1771026723.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,290 F1 · date: Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 30,020 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000037 · wk-form4_1742341865.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,020 Underlying: Common Stock · 30,020 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000037 · wk-form4_1742341865.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,915 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 16,249 | $69.44 | $1,128,330.56 |
DisclosureSEC source: 0001048477-25-000037 · wk-form4_1742341865.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,975 Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000015 · wk-form4_1740701728.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,224 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000015 · wk-form4_1740701728.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,857 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 00:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000015 · wk-form4_1740701728.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,197 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 40,850 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000112 · wk-form4_1717107477.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,850 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,779 | $75.29 | $209,225.35 |
DisclosureSEC source: 0001048477-24-000112 · wk-form4_1717107477.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,157 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. F3 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $75.00 to $75.735. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 38,071 | $74.46 | $2,834,576.31 |
DisclosureSEC source: 0001048477-24-000112 · wk-form4_1717107477.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,936 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. F2 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $74.12 to $74.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 40,850 | $63.10 | $2,577,635.00 |
DisclosureSEC source: 0001048477-24-000112 · wk-form4_1717107477.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. Read SEC document |
| May 02, 2024 Filed May 6, 2024 20:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 1,850 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000075 · wk-form4_1715028307.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,850 Underlying: Common Stock · 1,850 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 02, 2024 Filed May 6, 2024 20:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,850 | $85.01 | $157,268.50 |
DisclosureSEC source: 0001048477-24-000075 · wk-form4_1715028307.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,157 F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. F3 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $85.00 to $85.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 02, 2024 Filed May 6, 2024 20:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,850 | $63.10 | $116,735.00 |
DisclosureSEC source: 0001048477-24-000075 · wk-form4_1715028307.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. Read SEC document |
| April 30, 2024 Filed May 6, 2024 20:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 301 | $68.65 | $20,662.45 |
DisclosureSEC source: 0001048477-24-000075 · wk-form4_1715028307.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,157 F1 · date: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 24,602 | $88.34 | $2,173,340.68 |
DisclosureSEC source: 0001048477-24-000054 · wk-form4_1712004839.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,856 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 22,990 | $0.00 Strike: $83.87 | $0.00 |
DisclosureSEC source: 0001048477-24-000048 · wk-form4_1710895967.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,990 Underlying: Common Stock · 22,990 shares Expires 2034-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 21,699 | $83.87 | $1,819,895.13 |
DisclosureSEC source: 0001048477-24-000048 · wk-form4_1710895967.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,458 Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000048 · wk-form4_1710895967.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,157 F1 · price: Restricted stock units granted March 15, 2024. Price not applicable. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000026 · wk-form4_1709244996.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,897 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · acquired: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · acquired: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000026 · wk-form4_1709244996.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,613 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · acquired: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · acquired: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000026 · wk-form4_1709244996.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,550 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · acquired: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · acquired: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 23:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 13,764 | $95.30 | $1,311,709.20 |
DisclosureSEC source: 0001048477-23-000059 · wk-form4_1702595890.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,710 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 13, 2023. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 23:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 11,000 | $89.42 | $983,661.80 |
DisclosureSEC source: 0001048477-23-000033 · wk-form4_1691622498.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,474 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $89.39 to $89.52. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030719 · doc4.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,474 F2 · date: On May 16, 2023 the reporting person gifted 210 shares to an educational institution. Read SEC document |
| April 28, 2023 Filed May 18, 2023 21:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 317 | $66.88 | $21,200.96 |
DisclosureSEC source: 0001209191-23-030719 · doc4.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,684 F1 · date: Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 16, 2023 Filed Mar 18, 2023 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 19,957 | $93.41 | $1,864,183.37 |
DisclosureSEC source: 0001567619-23-005292 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,367 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 20,320 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005292 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,320 Underlying: Common Stock · 20,320 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,025 | $87.74 | $265,413.50 |
DisclosureSEC source: 0001567619-23-005292 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,324 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 8,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005292 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,349 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 7,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014614 · doc4.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,449 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014614 · doc4.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,025 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014614 · doc4.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,925 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| February 24, 2023 Filed Mar 1, 2023 02:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,474 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-003998 · doc1.xml · derivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,474 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 24, 2023 Filed Mar 1, 2023 02:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,474 | $67.81 | $99,951.94 |
DisclosureSEC source: 0001567619-23-003998 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2022 Filed Aug 12, 2022 01:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 47,526 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-22-015635 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,526 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| August 09, 2022 Filed Aug 12, 2022 01:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 47,526 | $95.93 | $4,559,169.18 |
DisclosureSEC source: 0001567619-22-015635 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,251 F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $95.540 to $96.400. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| August 09, 2022 Filed Aug 12, 2022 01:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 47,526 | $67.81 | $3,222,738.06 |
DisclosureSEC source: 0001567619-22-015635 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2022 Filed Aug 12, 2022 01:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,690 | $96.34 | $355,494.60 |
DisclosureSEC source: 0001567619-22-015635 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,251 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $96.310 to $96.425. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 23:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,398 | $90.00 | $665,820.00 |
DisclosureSEC source: 0001567619-22-013886 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,941 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 4, 2022. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,347 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-009494 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,347 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 4, 2022. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.